Rivaroxaban for the treatment of cerebral venous thrombosis
Abstract Background New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-02-01
|
| Series: | BMC Neurology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12883-021-02091-1 |
| _version_ | 1818953325160169472 |
|---|---|
| author | Sara Esmaeili Meysam Abolmaali Sobhan Aarabi Mohammad Reza Motamed Samira Chaibakhsh Mohammad Taghi Joghataei Mohammad Mojtahed Zahra Mirzaasgari |
| author_facet | Sara Esmaeili Meysam Abolmaali Sobhan Aarabi Mohammad Reza Motamed Samira Chaibakhsh Mohammad Taghi Joghataei Mohammad Mojtahed Zahra Mirzaasgari |
| author_sort | Sara Esmaeili |
| collection | DOAJ |
| description | Abstract Background New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in Cerebral venous thrombosis (CVT). This study aims to assess the effectiveness and bleeding risk of Rivaroxaban in comparison with Warfarin for the treatment of CVT. Materials and methods 36 patients with diagnosis of CVT were included. Clinical and background information was assessed on admission and patients were followed for at least 12 months. Measured outcomes were modified Rankin Scale (mRS), evidence of recanalization on contrast-enhanced Brain MR venography (MRV) and major or minor bleeding. Patients were divided into two groups according to the type of oral anticoagulant (Rivaroxaban vs Warfarin). Groups were compared in terms of final outcomes and side effects. Result Overall, 13 (36.11%) patients received Warfarin and 23 (63.89%) received Rivaroxaban. Optimal mRS score (0–1) was attained in 9 of 10 (90%) of patients treated with Rivaroxaban and 19 of 22 (86.36%) of patients received Warfarin. MRV showed complete or partial recanalization in 12 of 14 (85.71%) patients treated with Rivaroxaban and all patients in the Warfarin group. There was no significant difference between the two groups in terms of major and minor hemorrhage. Conclusion Rivaroxaban holds promise for the treatment of CVT. |
| first_indexed | 2024-12-20T10:04:28Z |
| format | Article |
| id | doaj.art-3a654f6ed1dd486bae7af8e2dca4aa5c |
| institution | Directory Open Access Journal |
| issn | 1471-2377 |
| language | English |
| last_indexed | 2024-12-20T10:04:28Z |
| publishDate | 2021-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Neurology |
| spelling | doaj.art-3a654f6ed1dd486bae7af8e2dca4aa5c2022-12-21T19:44:14ZengBMCBMC Neurology1471-23772021-02-012111610.1186/s12883-021-02091-1Rivaroxaban for the treatment of cerebral venous thrombosisSara Esmaeili0Meysam Abolmaali1Sobhan Aarabi2Mohammad Reza Motamed3Samira Chaibakhsh4Mohammad Taghi Joghataei5Mohammad Mojtahed6Zahra Mirzaasgari7Student Research Committee, Iran University of Medical SciencesStudent Research Committee, Iran University of Medical SciencesDepartment of Neurology, Firoozgar Hospital, Iran University of Medical SciencesDepartment of Neurology, Firoozgar Hospital, Iran University of Medical SciencesEye Research Center, The Five Senses Institute Rassoul Akram Hospital, Iran University of Medical SciencesCellular and Molecular Research Center, Iran University of Medical SciencesSchool of Advanced Technologies in Medicine, Iran University of Medical SciencesDepartment of Neurology, Firoozgar Hospital, Iran University of Medical SciencesAbstract Background New Oral Anticoagulants (NOACs) such as Rivaroxaban are introduced as alternatives to conventional vitamin-K antagonists in the long-term treatment of thrombotic events due to their lower bleeding risk. There is a lack of evidence on the effectiveness and safety of Rivaroxaban in Cerebral venous thrombosis (CVT). This study aims to assess the effectiveness and bleeding risk of Rivaroxaban in comparison with Warfarin for the treatment of CVT. Materials and methods 36 patients with diagnosis of CVT were included. Clinical and background information was assessed on admission and patients were followed for at least 12 months. Measured outcomes were modified Rankin Scale (mRS), evidence of recanalization on contrast-enhanced Brain MR venography (MRV) and major or minor bleeding. Patients were divided into two groups according to the type of oral anticoagulant (Rivaroxaban vs Warfarin). Groups were compared in terms of final outcomes and side effects. Result Overall, 13 (36.11%) patients received Warfarin and 23 (63.89%) received Rivaroxaban. Optimal mRS score (0–1) was attained in 9 of 10 (90%) of patients treated with Rivaroxaban and 19 of 22 (86.36%) of patients received Warfarin. MRV showed complete or partial recanalization in 12 of 14 (85.71%) patients treated with Rivaroxaban and all patients in the Warfarin group. There was no significant difference between the two groups in terms of major and minor hemorrhage. Conclusion Rivaroxaban holds promise for the treatment of CVT.https://doi.org/10.1186/s12883-021-02091-1Cerebral venous thrombosisRivaroxabanWarfarinRecanalizationBleeding risk |
| spellingShingle | Sara Esmaeili Meysam Abolmaali Sobhan Aarabi Mohammad Reza Motamed Samira Chaibakhsh Mohammad Taghi Joghataei Mohammad Mojtahed Zahra Mirzaasgari Rivaroxaban for the treatment of cerebral venous thrombosis BMC Neurology Cerebral venous thrombosis Rivaroxaban Warfarin Recanalization Bleeding risk |
| title | Rivaroxaban for the treatment of cerebral venous thrombosis |
| title_full | Rivaroxaban for the treatment of cerebral venous thrombosis |
| title_fullStr | Rivaroxaban for the treatment of cerebral venous thrombosis |
| title_full_unstemmed | Rivaroxaban for the treatment of cerebral venous thrombosis |
| title_short | Rivaroxaban for the treatment of cerebral venous thrombosis |
| title_sort | rivaroxaban for the treatment of cerebral venous thrombosis |
| topic | Cerebral venous thrombosis Rivaroxaban Warfarin Recanalization Bleeding risk |
| url | https://doi.org/10.1186/s12883-021-02091-1 |
| work_keys_str_mv | AT saraesmaeili rivaroxabanforthetreatmentofcerebralvenousthrombosis AT meysamabolmaali rivaroxabanforthetreatmentofcerebralvenousthrombosis AT sobhanaarabi rivaroxabanforthetreatmentofcerebralvenousthrombosis AT mohammadrezamotamed rivaroxabanforthetreatmentofcerebralvenousthrombosis AT samirachaibakhsh rivaroxabanforthetreatmentofcerebralvenousthrombosis AT mohammadtaghijoghataei rivaroxabanforthetreatmentofcerebralvenousthrombosis AT mohammadmojtahed rivaroxabanforthetreatmentofcerebralvenousthrombosis AT zahramirzaasgari rivaroxabanforthetreatmentofcerebralvenousthrombosis |